The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III randomized trial of metformin versus placebo on recurrence and survival in early-stage breast cancer (BC) (NCIC Clinical Trials Group MA.32).
W. Parulekar
No relevant relationships to disclose
B. E. Chen
No relevant relationships to disclose
C. Elliott
No relevant relationships to disclose
L. E. Shepherd
No relevant relationships to disclose
K. A. Gelmon
No relevant relationships to disclose
K. I. Pritchard
Honoraria - Abraxis BioScience; Boehringer Ingelheim; Novartis; Pfizer; Roche
Expert Testimony - AstraZeneca (U); Novartis (U)
T. J. Whelan
No relevant relationships to disclose
J. A. Ligibel
No relevant relationships to disclose
D. L. Hershman
No relevant relationships to disclose
I. A. Mayer
No relevant relationships to disclose
T. J. Hobday
No relevant relationships to disclose
P. Rastogi
No relevant relationships to disclose
J. Lemieux
No relevant relationships to disclose
P. A. Ganz
No relevant relationships to disclose
V. Stambolic
No relevant relationships to disclose
P. J. Goodwin
Research Funding - Novartis